TICHENOR MCHENRY T 4
4 · NGM BIOPHARMACEUTICALS INC · Filed Apr 10, 2019
Insider Transaction Report
Form 4
TICHENOR MCHENRY T
Director
Transactions
- Conversion
Common Stock
2019-04-08+1,833,332→ 1,872,314 total(indirect: See Footnote) - Conversion
Series C Convertible Preferred Stock
2019-04-08−166,666→ 0 total(indirect: See Footnote)→ Common Stock (166,666 underlying) - Conversion
Series B Convertible Preferred Stock
2019-04-08−1,616,666→ 0 total(indirect: See Footnote)→ Common Stock (1,616,666 underlying) - Conversion
Series D Convertible Preferred Stock
2019-04-08−50,000→ 0 total(indirect: See Footnote)→ Common Stock (50,000 underlying)
Footnotes (3)
- [F1]Every two shares of Series B preferred stock, Series C preferred stock and Series D preferred stock automatically converted into one share of common stock in connection with the closing of the issuer's initial public offering. These shares have no expiration date.
- [F2]The Reporting Person, a Director of the Issuer, is the President and managing partner of Tichenor Ventures, LLC and has sole voting and investment power with respect to such shares.
- [F3]The shares are beneficially owned by Tichenor Ventures, LLC